#United States #Richmond #Automation #Drug Testing #Alps Dx

Alps Dx Official Launch: A New Era for Oral Fluid Drug Testing

Alps Dx has officially launched, marking a significant development in the realm of diagnostics technology. As an innovative company focused on improving oral fluid drug testing, Alps Dx seeks to modernize the industry through enhanced speed, safety, and scalability of testing techniques. This initiative emerges against a backdrop of longstanding inefficiencies that have limited the widespread adoption of oral fluid testing in both clinical and forensic settings.

The company is spearheaded by a team of industry veterans, with co-founder and Chief Scientific Officer Les Edinboro emphasizing the need for change within the sector. "Oral fluid testing has long been recognized for its potential to provide a more patient-friendly approach to toxicology. However, the process has suffered due to manual and inconsistent pre-analytical workflows that contribute to delays and operational strain," Edinboro noted during the launch announcement.

In response to these challenges, Alps Dx aims to introduce a connected, automated solution that rethinks how oral fluid samples are handled from collection through to analysis. Ali Safavi, President and CEO, articulates the vision as one that will overhaul outdated methods: "Alps Dx will replace the cumbersome and sometimes uncomfortable sample collection process with a streamlined, automated solution that enhances the overall experience while reducing errors across the board."

The leadership team combines scientific prowess and operational expertise, with Ali Safavi at the helm as a serial entrepreneur who has consistently championed efficiency in laboratory operations. Les Edinboro, with his extensive background in toxicology at one of the largest diagnostics organizations globally, brings a wealth of knowledge to the company. Together with diagnostics executive Greg Ourednik and engineering innovator Brian Sorel, they form a robust team capable of tackling the ongoing challenges within the laboratory environment.

Central to Alps Dx’s mission is the commitment to improving lives by making oral fluid drug testing more accessible for various stakeholders, including businesses and employees. The aim is to enable laboratories to transition to faster, safer, and more efficient automated workflows. To realize this goal, Alps Dx is developing an array of products designed to automate the sample journey across the pre-analytical continuum. This includes an application platform, collection kits, consumables, and integrated software applications, all functioning as a cohesive system.

Set to be introduced in 2026, Alps Dx's connected portfolio will feature instruments for automated sample processing, enhanced filtration tools for oral fluid, guided workflow software, an intuitive mobile app for tracking sample identification, and a next-generation oral fluid collection device currently under development. Collectively, these innovations promise to eliminate manual handling, enhance sample integrity, and allow laboratories to operate with greater efficiency and reliability.

The company is poised to unveil its first automated instrument in collaboration with a leading laboratory robotics firm, with specific launch details expected to follow shortly.

With its commitment to modernizing oral fluid testing and addressing the associated inefficiencies, Alps Dx is not just stepping into the market; it is looking to redefine how drug testing is conducted, ensuring better outcomes for all.

About Alps Dx

Alps Dx is dedicated to developing automated technologies that enhance the sample collection and pre-analytical processes for drug testing. Its diverse portfolio comprises purpose-built instruments, consumables, and workflow software aimed at helping laboratories improve efficiency while ensuring the highest standards of patient care. Headquartered in Richmond, Virginia, Alps Dx is set to make a lasting impact on the diagnostic landscape. For additional information, visit alpsdx.com.